secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2022-09-22T23:59:59+00:00
Accession:  0000320017-22-000085
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lisata halts XOWNA FREEDOM Trial; development now contingent on partner
-----------------------------------------------------------------------

- Phase 2b FREEDOM Trial of XOWNA (autologous CD34+ cells) suspended May 2022 due to COVID enrollment challenges and heterogeneity.
- Interim analysis of first 20 patients with 6-month follow-up completed; board decided redesigned trial is needed but prohibitively expensive alone.
- XOWNA development will only continue if a strategic partner is identified and secured to fund a redesigned trial.
- No assurance that a partner can be found or that acceptable terms will be reached.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000032001722000085/0000320017-22-000085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000032001722000085/clbs-20220922.htm
  HTML page:      https://secwatch.observer/filing/0000320017-22-000085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer